Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can your breath predict radiation side effects? new study investigates

NCT ID NCT04081428

Knowledge-focused Sponsor: NHS Lothian Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at new ways to predict how prostate cancer and nearby healthy tissues react to a precise type of radiation therapy called SBRT. Researchers will analyze breath samples, blood DNA, and CT scans from 60 men with low- or intermediate-risk prostate cancer. The goal is to find markers that could help doctors personalize treatment to improve cure rates and reduce side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2018

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Men diagnosed with localised prostate cancer within the South East of Scotland cancer network who are suitable for study entry

Ages

18 to 80 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Low risk prostate cancer T1-2, PSA\<10ng/ml, Gleason score (GS) 3+3=6 * Intermediate risk prostate cancer T1-T2, PSA 10-20ng/ml,GS ≤7(3+4=7 only) * World Health Organisation (WHO) performance status 0-2 * Prostate volume ≤90cc * International Prostate Symptom Score (IPSS) ≤20 * Peak urinary flow rate (Q-max) \>10cc/sec * Urinary residual \<250mls total * No prior Trans Urethral Resection of the Prostate (TURP) * No previous pelvic radiotherapy * Able to give informed consent * Aged between 18-85 years of age Exclusion Criteria: * Inflammatory bowel disease * Previous androgen deprivation therapy * History of urinary retention

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DNA damage are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DNA damage Prostate cancer Radiotherapy side effects Volatile organic compounds

Contacts and locations

Locations

  • Edinburgh Cancer Centre, Western General Hospital

    Edinburgh, Mid Lothian, EH4 2XU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.